Bayer Pharma Aktiengesellschaft

Boehringer Ingelheim International Gmbh

Bayer Aktiengesellschaft

Other

Bayer Intellectual Property Gmbh

Bayer Healthcare Aktiengesellschaft

Bayer Pharmaceuticals Corporation

Nils Burkhardt

Karl-Heinz Schlemmer

Martin Hendrix

Adrian Tersteegen

Joachim Schuhmacher

Susanne Röhrig

Johannes Köbberling

Michael Sperzel

Christian Stegmann

Manuel Ellermann

Tom Kinzel

Maria Köllnberger

Kristin Beyer

Matthias Werner

Hilmar Bischoff

Christina Erb

Marja Van Kampen

Frank-Gerhard Böβ

Cristina Alonso-Alija

Mary F Fitzgerald

Nigel J Cuthbert

Volker Geiss

Maria Niewöhner

Dagmar Schauss

Jorma Haßfeld

Paul Naab

Yolanda Cancho Grande

Marcus Bauser

Jens-Kerim Ergüden

Dietmar Flubacher

Graham Sturton

Andreas Schade

Klaus Ochmann

Bernd Kalthof

Jürgen Stoltefuss

Yolanda Cancho-Grande

Michael Harnau

Karl-Hermann Koeching

Georg Schmidt

Martin Michels

Mike Küster

Linn Schneider

Heike Gielen

Stefan Heitmeier

Olaf Weber

Dagmar Karthaus

Heike Gielen-Haertwig

Stephen Boyer

Arno Friedl

Reinhard Jork

Jorma Haβfeld

Maria Niewöhner, Legal Representative

Susanne Rohrig

Jorma Hassfeld

Irene Gerlach

Michael Schauer

Maria Theresia Niewohner, Legal Representative

Jan Stampfuß

Volker Hinz

David Brückner

Thorsten-Oliver Repp

Andrea Sewing

Mark Miglarese

Gaelle Valot

Imke Meyer

Richard Graham Sturton

Jörg Heiermann

Willem Jan Hengeveld

Thorsten Oliver Repp

Maria Kollnberger

Johannes Kobberling

Frank-Gerhard Boess

Frank Gerhard Boess

A dispensing device includes a housing having at least one pressure chamber, having a supply opening for the supply of liquid into the pressure chamber and having a multiplicity of conduits between the pressure chamber and an external side of the housing, there being situated in each of the conduits a tube, the first end of which protrudes into the pressure chamber and the second end of which protrudes out of the housing on the external side.

Metering device

A method and a system for rapid kinetic fluorescence measurement in high-throughput screening with high time-resolution includes providing a microtiter plate having a transparent base and multiple assay wells, a dispensing system arranged above the microtiter plate for simultaneously adding liquid into multiple assay wells, an illumination system beneath the microtiter plate for illuminating the multiple assay wells simultaneously through the transparent base, a detection system for detecting electromagnetic radiation from the multiple assay wells simultaneously through the transparent base, adding 0.3-300 &#x3bc;l of liquid per assay well from the dispensing system into the multiple assay wells, illuminating the multiple assay wells simultaneously through the transparent base using the illumination system before or from the time point of the start of the addition, detecting the electromagnetic radiation from the multiple assay wells simultaneously at a time interval of 1-1000 ms between individual measurement points.

Method and system for taking measurements in a high-throughput screening with high time resolution

The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.

(Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use

The present application relates to novel substituted piperidinylpyrazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired hemostatic disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of heavy menstrual bleeding, postpartum hemorrhage, hemorrhagic shock, hemorrhagic cystitis, gastrointestinal hemorrhage, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.

Piperidinylpyrazolopyrimidinones and their use

The invention relates to methods for detecting pyrophosphate by means of bioluminescence detection. In addition, methods for measuring chemical, especially enzyme-catalyzed, reactions in which pyrophosphate is formed or consumed are described. Such reactions are catalyzed for example by guanylyl cyclases, adenylyl cyclases, DNA polymerases or RNA polymerases. The novel methods are distinguished by high sensitivity and low susceptibility to interference, can easily be automated and miniaturized and are additionally suitable for carrying out continuous measurements. The methods can be employed particularly advantageously in the area of medical diagnosis and biomedical research, including pharmaceutical active ingredient research.

Method for detecting pyrophosphate by means of bioluminescence detection

The invention relates to alkyl-substituted pyrazolopyrimidines, process for their preparation, and the use thereof for producing medicaments for improving learning and/or memory. The alkyl-substituted pyrazolopyrimidines are of the formula (I): with the variables as defined in the claims.

Alkyl-substituted pyrazolopyrimidines

The invention relates to novel phenyl-substituted pyrazolopyrimidines, process for their preparation, and their use for producing medicaments for improving perception, concentration, learning and/or memory.

Phenyl-substituted pyrazolopyrimidines

The invention relates to novel alkyl-substituted pyrazolopyrimidines, process for their preparation, and the use thereof for producing medicaments for improving perception, concentration, learning and/or memory with compounds of formula (I): 

Substituted pyrazolo[3,4-d]pyrimidin-4-one compounds as phosphodiesterase inhibitors

The invention relates to 7-(4-tert butyl-cyclohexyl)-imidazotriazinones, processes for their preparation and their use in medicaments, esp. for the treatment and/or prophylaxis of inflammatory processes and/or immune diseases.

Heterocycles 3

The invention relates to novel 5-Ethyl-imidazotriazinones, processes for their preparation and their use in medicaments, esp. for the treatment and/or prophylaxis of inflammatory processes and/or immune diseases.

5-Ethyl-imidazotriazinones

The invention relates to novel 5-ethyl-imidazotriazinones, processes for their preparation and their use in medicaments, esp. for the treatment and/or prophylaxis of inflammatory processes and/or immune diseases.

5-ethylimidarotriazones

The invention relates to new imidazotriazines, processes for their preparation, and their use for the production of medicaments for the treatment and/or prophylaxis of neurodegenerative disorders, in particular Parkinson's disease.

Imidazotriazines for use as phosphodiesterase inhibitors

The present invention relates to pyrrolo[2.1-a]dihydroisoquinolines which are inhibitors of phosphodiesterase 10a and can be used for combating cancer.

Pyrrolo (2.1a)dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors

Growing community of inventors

Velbert, Germany

Nils Burkhardt